Pharmacological fixed relationships for treating hematopoietic cancers and proliferative disorders

A pharmaceutical composition comprising cytarabine and daunorubicin at a mole fixed relationship nonantagonistic cytarabine regarding daunorubicin about 5: 1 for use in the treatment of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) in a human patient, wherein said non-antagonistic mole ratio fixed cytarabine regarding daunorubicin is encapsulated in liposomes distearoyl comprise phosphatidyl choline (DSPC), distearoyl phosphatidyl glycerol (DSPG) and cholesterol in a molar ratio DSPC: DSPG: cholesterol 7 : 2: 1; wherein a dose of said composition is administered intravenously over 3 hours or less; wherein the dose of said composition is from 32 to 134 units per m2, where 1 unit is 1 mg and 0.44 mg of cytarabine, daunorubicin; and wherein said composition is administered in a dosing schedule on days 1, 3 and 5.